• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

比利时弗拉芒地区5岁儿童对麻疹、腮腺炎和风疹的易感性。

Susceptibility to measles, mumps, and rubella in 5-year-old children in Flanders, Belgium.

作者信息

Leuridan E, Maertens K, Wautier M, Hutse V, Theeten H

机构信息

Centre for the Evaluation of Vaccination, Vaccine and Infectious Diseases Institute, University of Antwerp, Universiteitsplein 1, 2610, Wilrijk, Belgium,

出版信息

Eur J Pediatr. 2015 Jul;174(7):925-32. doi: 10.1007/s00431-014-2481-5. Epub 2015 Jan 13.

DOI:10.1007/s00431-014-2481-5
PMID:25579232
Abstract

UNLABELLED

The second dose of an MMR vaccine is a catch up for persons who did not receive the first dose or for primary vaccine failures. Catch up doses can be scheduled according to convenience into the program of the country. The second MMR dose is often administered at the age of 5 years, before school entry. Some countries chose to implement the second dose at the age of 10-13 years, as is the case for Belgium. The here presented long-term follow-up of a cohort of children, set up originally to analyze maternal antibodies against vaccine preventable diseases, offers a unique opportunity to evaluate ad interim the current long-interval MMR vaccination schedule in Belgium. After 1 MMR dose at 12 months of age, rubella immunity is almost intact at 5 years of age (94.5 % is seropositive), measles seropositivity scores 86.8 %, and mumps 32 %, measured with ELISA. A seroneutralization (SN) test for mumps antibodies reveals much higher seropositivity rates (88 %). Using a regression model on the log (IgG) titer for all antigens, no influence was found from any of the studied variables, except for girls who had a significantly higher rubella IgG titer (p=0.002) compared to boys.

CONCLUSION

The data show considerable susceptibility to mumps and measles in 5-year-old children, confirming a previously conducted seroprevalence study (2006). Both advantages and disadvantages of shortening or enlarging the vaccine schedule are discussed.

摘要

未标注

麻腮风疫苗的第二剂是针对未接种第一剂或初次疫苗接种失败的人群的补种剂次。补种剂次可根据各国的便利情况安排到国家计划中。麻腮风疫苗的第二剂通常在5岁入学前接种。一些国家选择在10至13岁时接种第二剂,比利时就是这种情况。这里介绍的一组儿童的长期随访最初是为了分析母体针对疫苗可预防疾病的抗体而设立的,这为临时评估比利时目前的长间隔麻腮风疫苗接种计划提供了一个独特的机会。在12月龄接种一剂麻腮风疫苗后,5岁时风疹免疫力几乎完好(94.5%呈血清阳性),麻疹血清阳性率为86.8%,腮腺炎为32%(采用酶联免疫吸附测定法测定)。腮腺炎抗体的血清中和(SN)试验显示血清阳性率高得多(88%)。对所有抗原的对数(IgG)滴度使用回归模型,除了女孩的风疹IgG滴度显著高于男孩(p=0.002)外,未发现任何研究变量有影响。

结论

数据显示5岁儿童对腮腺炎和麻疹有相当高的易感性,证实了之前进行的血清流行率研究(2006年)。讨论了缩短或延长疫苗接种计划的利弊。

相似文献

1
Susceptibility to measles, mumps, and rubella in 5-year-old children in Flanders, Belgium.比利时弗拉芒地区5岁儿童对麻疹、腮腺炎和风疹的易感性。
Eur J Pediatr. 2015 Jul;174(7):925-32. doi: 10.1007/s00431-014-2481-5. Epub 2015 Jan 13.
2
Measles-mumps-rubella revaccination; 18 months vs. 4-6 years of age: potential impacts of schedule changes.麻疹-腮腺炎-风疹疫苗复种;18 个月与 4-6 岁:接种程序改变的潜在影响。
J Trop Pediatr. 2011 Oct;57(5):347-51. doi: 10.1093/tropej/fmq102. Epub 2010 Nov 14.
3
Antibody persistence in children aged 6-7years one year following booster immunization with two MMR vaccines applied by aerosol or by injection.6至7岁儿童在通过气溶胶或注射方式接种两剂麻疹、腮腺炎和风疹联合疫苗加强免疫一年后的抗体持久性。
Vaccine. 2017 May 25;35(23):3116-3122. doi: 10.1016/j.vaccine.2017.04.027. Epub 2017 Apr 28.
4
Similar Antibody Levels in 3-Year-Old Children Vaccinated Against Measles, Mumps, and Rubella at the Age of 12 Months or 18 Months.12个月或18个月大时接种麻疹、腮腺炎和风疹疫苗的3岁儿童体内抗体水平相似。
J Infect Dis. 2016 Jun 15;213(12):2005-13. doi: 10.1093/infdis/jiw058. Epub 2016 Feb 9.
5
Prevalence of IgG antibody against measles, mumps and rubella in bangladeshi children: a pilot study to evaluate the need for integrated vaccination strategy.孟加拉国儿童中麻疹、腮腺炎和风疹IgG抗体的流行率:一项评估综合疫苗接种策略必要性的试点研究。
Scand J Immunol. 2006 Dec;64(6):684-9. doi: 10.1111/j.1365-3083.2006.01857.x.
6
Immunogenicity and efficacy of one dose measles-mumps-rubella (MMR) vaccine at twelve months of age as compared to monovalent measles vaccination at nine months followed by MMR revaccination at fifteen months of age.与9个月时接种单价麻疹疫苗,随后在15个月时接种麻腮风(MMR)疫苗复种相比,12个月龄时接种一剂MMR疫苗的免疫原性和有效性。
Vaccine. 2001 Aug 14;19(31):4473-8. doi: 10.1016/s0264-410x(01)00207-9.
7
Immunogenicity and safety of a second dose of a measles-mumps-rubella vaccine administered to healthy participants 7 years of age or older: A phase III, randomized study.麻疹-腮腺炎-风疹疫苗第二剂在 7 岁及以上健康参与者中的免疫原性和安全性:一项 III 期、随机研究。
Hum Vaccin Immunother. 2018;14(11):2624-2631. doi: 10.1080/21645515.2018.1489186. Epub 2018 Jul 12.
8
Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life.在健康儿童生命的第二年,对一剂和两剂冰箱保存稳定的四价麻疹-腮腺炎-风疹-水痘疫苗后的免疫原性和安全性评估。
Pediatr Infect Dis J. 2008 Aug;27(8):724-30. doi: 10.1097/INF.0b013e318170bb22.
9
Long-term immunity to measles, mumps and rubella after MMR vaccination among children with bone marrow transplants.骨髓移植儿童接种MMR疫苗后对麻疹、腮腺炎和风疹的长期免疫力。
Bone Marrow Transplant. 2004 Jun;33(12):1187-90. doi: 10.1038/sj.bmt.1704476.
10
Difficulties in eliminating measles and controlling rubella and mumps: a cross-sectional study of a first measles and rubella vaccination and a second measles, mumps, and rubella vaccination.消除麻疹以及控制风疹和腮腺炎的困难:一项关于首剂麻疹和风疹疫苗接种以及第二剂麻疹、腮腺炎和风疹疫苗接种的横断面研究
PLoS One. 2014 Feb 20;9(2):e89361. doi: 10.1371/journal.pone.0089361. eCollection 2014.

引用本文的文献

1
Estimating the Transmissibility of Mumps: A Modelling Study in Wuhan City, China.估计腮腺炎的传播力:中国武汉市的一项建模研究
Front Med (Lausanne). 2021 Aug 3;8:683720. doi: 10.3389/fmed.2021.683720. eCollection 2021.
2
High risk of mumps infection in children who received one dose of mumps-containing vaccine: waning immunity to mumps in children aged 2-5 years from kindergartens in Jiangsu Province, China.在中国江苏省幼儿园,2-5 岁儿童接受一剂含腮腺炎疫苗后感染腮腺炎的高风险:腮腺炎免疫力下降。
Hum Vaccin Immunother. 2020 Jul 2;16(7):1738-1742. doi: 10.1080/21645515.2019.1708162. Epub 2020 Jan 24.
3
Seroprevalence of mumps before the introduction of mumps-containing vaccine in Lao PDR: results from a nationwide cross-sectional population-based survey.

本文引用的文献

1
Mumps increase in Flanders, Belgium, 2012-2013: results from temporary mandatory notification and a cohort study among university students.2012 - 2013年比利时弗拉芒地区腮腺炎疫情上升:临时强制报告结果及一项大学生队列研究
Vaccine. 2014 Jul 31;32(35):4393-4398. doi: 10.1016/j.vaccine.2014.06.069. Epub 2014 Jun 25.
2
Assessing mumps outbreak risk in highly vaccinated populations using spatial seroprevalence data.利用空间血清流行率数据评估高度接种疫苗人群中的腮腺炎暴发风险。
Am J Epidemiol. 2014 Apr 15;179(8):1006-17. doi: 10.1093/aje/kwu014. Epub 2014 Feb 25.
3
Assessing vaccination coverage in infants, survey studies versus the Flemish immunisation register: achieving the best of both worlds.
老挝人民民主共和国引入含腮腺炎疫苗之前腮腺炎的血清流行率:一项基于全国横断面人群调查的结果
BMC Res Notes. 2019 Mar 19;12(1):155. doi: 10.1186/s13104-019-4194-3.
4
Application of a mixture model to assess the effect of measles-mumps-rubella vaccine on the mumps epidemic in children from kindergarten to early school age in Jiangsu Province, China.应用混合模型评估麻疹-腮腺炎-风疹疫苗对中国江苏省幼儿园至小学低年级儿童腮腺炎流行的影响。
Hum Vaccin Immunother. 2018;14(11):2654-2659. doi: 10.1080/21645515.2018.1480239. Epub 2018 Jun 28.
5
Different measles outbreaks in Belgium, January to June 2016 - a challenge for public health.2016年1月至6月比利时不同的麻疹疫情——对公共卫生的一项挑战
Euro Surveill. 2016 Aug 11;21(32). doi: 10.2807/1560-7917.ES.2016.21.32.30313.
评估婴儿疫苗接种覆盖率:调查研究与佛兰德免疫登记系统的对比——兼收并蓄,两全其美。
Vaccine. 2014 Jan 9;32(3):345-9. doi: 10.1016/j.vaccine.2013.11.041. Epub 2013 Nov 21.
4
Timeliness of infant vaccination and factors related with delay in Flanders, Belgium.婴儿疫苗接种的及时性及在比利时佛兰德斯延迟接种的相关因素。
Vaccine. 2014 Jan 3;32(2):284-9. doi: 10.1016/j.vaccine.2013.10.084. Epub 2013 Nov 16.
5
Measles humoral and cell-mediated immunity in children aged 5-10 years after primary measles immunization administered at 6 or 9 months of age.6 或 9 月龄初免麻疹后 5-10 岁儿童的麻疹体液和细胞介导免疫。
J Infect Dis. 2013 Feb 15;207(4):574-82. doi: 10.1093/infdis/jis719. Epub 2013 Jan 8.
6
Seroepidemiology of mumps in Europe (1996-2008): why do outbreaks occur in highly vaccinated populations?欧洲流行性腮腺炎血清流行病学(1996-2008 年):为何在高接种疫苗人群中暴发流行?
Epidemiol Infect. 2013 Mar;141(3):651-66. doi: 10.1017/S0950268812001136. Epub 2012 Jun 12.
7
Maternal mumps antibodies in a cohort of children up to the age of 1 year.母亲巨细胞病毒抗体在一组 1 岁以下儿童中的研究。
Eur J Pediatr. 2012 Aug;171(8):1167-73. doi: 10.1007/s00431-012-1691-y. Epub 2012 Mar 7.
8
Who gets measles in Europe?在欧洲,谁会得麻疹?
J Infect Dis. 2011 Jul;204 Suppl 1:S353-65. doi: 10.1093/infdis/jir067.
9
Assessment of mumps virus-specific antibodies by different serological assays: which test correlates best with mumps immunity?不同血清学检测方法评估腮腺炎病毒特异性抗体:哪种检测方法与腮腺炎免疫力相关性最好?
Eur J Clin Microbiol Infect Dis. 2011 Oct;30(10):1223-8. doi: 10.1007/s10096-011-1216-z. Epub 2011 Apr 1.
10
MMR vaccination and disease elimination: the Finnish experience.麻疹、腮腺炎和风疹联合疫苗接种和疾病消除:芬兰经验。
Expert Rev Vaccines. 2010 Sep;9(9):1045-53. doi: 10.1586/erv.10.99.